BRCA1 and ovarian carcinoma: (111) also found that the PARP inhibitor Olaparib had radiosensitizing effects on both BRCA1-normal and -mutated high-grade plasmacytotic ovarian cancer cell lines, and the effect was more pronounced in BRCA1-mutated cells.